click enter text
initi outperform pt sweet portfolio action
invest view growth acceler ex-dent asset
year confirm invest cphd/pll increasingli
nobn ad growth technic profici organ
support innov assert promot spend trajectori
address concern flag analysi division-level
perform rel peer addit ge life scienc asset
cut cyclic exposur pro forma vs rais faster
growth/less cyclic biopharma exposur pro forma vs
offer highest pro-forma yield highest convers
tool ex agil cyclic uncertainti higher
up/down inflect bioprocess/pl sinc signal
modest acceler would off-set true industri slow
bode well trend survey confirm
share gain key lab custom exhibit
gener ge life scienc spend ge
life scienc estim accret year ultim hsd
cash return exhibit de-lever year ge deal
add organ growth reduc cyclic support higher
valuat framework pt deriv forecast
pro-forma ge ls deal target yield line
methodolog detail industri note forecast assum
increment free cash deploy return smaller return
assumpt vs peer given uncertainti around post ge cap deploy
trade fundament data
upsid target
price
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
shift toward life scienc visibl ep growth make strong invest case
exhibit summari impact ge life scienc acquisit
high visibl attract yield dhr effort
drive innov differenti portfolio
alongsid sharper commerci effort cphd/pall
greater scale across rang key end
market
equipment-heavi sustain mid-singl digit
organ grower one meaning less
cyclic year ago
last three year taken recur revenu
mix bp direct sale mix
bp gross margin bp ge
life scienc deal address prior concern
 lack clariti capit deploy
prioriti give us confid earn
growth profil near ep next two
year doubl digit growth beyond
revenu base
ge life scienc no-brain bioprocess
space alreadi oligopoli sort long
natur target consolid deal
take dhr exposur biolog
potenti bp total organ growth
categori alon exist pll
exposur bioprocess materi attract
includ concentr singl use filtrat
dhr acquisit ge life scienc round
portfolio higher exposur downstream
process chromatographi build upstream
cell cultur media singl use exposur
ebitda valuat nomin normal rel
recent comp though valuat full
opportun cost reduct compar
minor cap cash return deal deal
visibl medium term growth
synergi broader pharma platform
point under-emphas thu far much like
patheon expect leverag deeper
tie pharma compani drive growth across
pharma franchis forecast
accret year one guidanc
page
revenu mix shift life scienc acceler
note pro forma ge life scienc acquisit divestitur dental
move biolog also new
ge life scienc deal get headlin
appropri drive pharma
mix higher sinc pll acquisit
address histor under-index pharma
sciex franchis custom focu
histor appli market pll
invest drive innov
exampl intern develop system
autom optim continu manufactur
effect deliv singl room singl sourc
option enabl faster turnaround time
product batch bioprocess
time commerci optim pll take new
project flow per year bellweth
bioprocess sale
grow compound-annual-growth-rate over-index
singl use system mix grow
exhibit bioprocess categori organ growth
exhibit forecast growth biolog manufactur
page
categori organ quantiti kg/yr forecast bulk kg productcommercialbla/maa/ndaphas pro formadanah revenu mix segmentdhr dentalenviro/applieddiagnosticslif scienc
survey
environ
survey analysi highlight two posit life
scienc lab survey intend
primarili address trend market share
waters/thermofisher/agil share dynam
pharma academ lab space histor
found
meaning share trend danaher/sciex
unsurpris given
compani
limit concentr pure life scienc
food/environmental/clin market first
time experi pick share trend
sciex meaning posit
suggest phenomenex lc column effort
gain traction core life scienc lab
high visibl medium term goal
medium term framework attract de-risk ge transact decemb introduc
new public long term financi framework msd organ growth arguabl tmo new
level margin expans per year slightli tmo convers line
trend upsid trend known tie outlook suggest
ep growth outlook absent contribut ge deal ge deal model impli ep growth
compound-annual-growth-rate next year unsurprisingli target rang capit deploy
exhibit mid-term framework vs wolf consensu
exhibit medium term growth margin target
note wolf ep compound-annual-growth-rate pro forma ge ls acquisit impact
page
long-term frameworkwolf cagrcor revenu growthmid singl averagecor oper margin cagrfcf net incom ep sciex anticip market share chang previou month vs next month data bp msconsum softwarelc
separ dental provid greater attent dental margin
dental spin right move outlin recent work hsic/pdco/xray dental space share
littl life sciences/diagnost space asid high consum mix though right point
consum tie specif hardwar larg major case continu
anticip spin dental asset late though effect rais capit partial fund ge
life scienc acquisit continu call improv growth dental cite stabil inventori level
channel mix shift specialti emerg market expand product line target digital/specialti
categori dental franchis averag lag bp organ recent year track
gener slower vs ex-inventori howev evolv product mix toward specialti
consum mix vs prior sold direct faster growth market agre
take growth higher mix execut critic question relat margin comp
includ suggest goal achiev consolid dental oper unit
cut redund hardwar line cut real estat footprint recent margin pressur
function expand sale rep/commerci spend acceler spend may posit better reach
broader array custom direct compani provid dental practic use
page
growth acceler possibl life scienc shift
exhibit growth track closer peer averag
note differ organ revenu growth wolf weight
averag tool coverag
exhibit organ growth trend pall busi vs bioprocess industri
page
exhibit wolf forecast organ margin
exhibit margin expans driven multipl factor
note top bar repres report margin expans given year
includ affx pthn fei life
impacts/synergi relev year
exhibit wolf forecast organ margin expans
exhibit histor forecast growth
note agil includ keysight bill fx ilab multiplicom
dilut pension chang bond yield includ charg
page
exhibit overal margin dental margin vs
ahead peer group ahead consensu
note organ growth consensu estim consensu nomin
growth estim less wolf estim inorgan impact revenu fx
note reflect medic devic divis
 sell day
exhibit leverag ge deal dental ipo exhibit alloc
page
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium compound-annual-growth-rate
page
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
 sale detail mn adjust sell revenu wr organ bp bpsm estimate bp bp bp bp bp bp bp bp bp bpsother estimate bp bp bp bp bp bp bp bp bp bp bp bp bp wr organ bp bpsm bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp bp bp wr organ bp bpsm bp bp bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp wr organ bp bp bp bp bp bp bp bp bp bp bp bp bp bpsother bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp bp
note figur million unless state per-shar term
page
 balanc term current debt less current incom l-t total equiti asset invest capit goodwil debt debt per debt debt sale outstand day payabl outstand convers
note figur million unless state per-shar term
page
 cont work continu dc continu dc sstock free share
